Zimberelimab
- Generic Name
- Zimberelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2259860-24-5
- Unique Ingredient Identifier
- ZBL7O904IL
- Indication
用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。
- Associated Conditions
- -
- Associated Therapies
- -
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT06082960
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06055738
- Locations
- 🇨🇳
Hongxi Zhao, Xi'an, Shaanxi, China
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Gulam Manji
- Target Recruit Count
- 60
- Registration Number
- NCT06048484
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Nataliya Uboha
- Target Recruit Count
- 39
- Registration Number
- NCT06048133
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Catherine Spina
- Target Recruit Count
- 23
- Registration Number
- NCT05915442
- Locations
- 🇺🇸
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT05891171
- Locations
- 🇺🇸
Mayo Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Florida, Jacksonville, Florida, United States
🇺🇸Affinity Health Hope and Healing Cancer Services, LLC, Hinsdale, Illinois, United States
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05886634
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Study of GS-4528 in Adults With Solid Tumors
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 132
- Registration Number
- NCT05840224
- Locations
- 🇨🇳
Chang Gung Memorial Hospital Linkuo Branch of the Chang Gung Medical Foundation, Taoyuan, Taiwan
🇺🇸The University of Washington/FHCC, Seattle, Washington, United States
🇪🇸START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I, Madrid, Spain
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 33
- Registration Number
- NCT05824468
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, China
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT05759312
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.